会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • METHOD OF PRODUCING ULTRAFINE CRYSTALLINE TIN/TIB2 COMPOSITE CERMET
    • 生产超细晶体TIN / TIB2复合陶瓷的方法
    • US20090129962A1
    • 2009-05-21
    • US11942147
    • 2007-11-19
    • JAE HYEOK SHIMJI WOO KIMYOUNG WHAN CHO
    • JAE HYEOK SHIMJI WOO KIMYOUNG WHAN CHO
    • B22F7/00B22F3/10
    • C22C29/005C22C1/053C22C33/0278
    • Disclosed herein is a method of producing an ultrafine crystalline TiN/TiB2 composite cermet. In the method, titanium nitride (TiN)/titanium boride (TiB2)/stainless steel composite nanopowder is produced through a reaction milling process using titanium (Ti), boron nitride (BN), and stainless steel powders as raw material powders, and the resulting composite nanopowder is liquid-phase sintered. The method comprises a first step of mixing titanium powder and boron nitride powder at a molar ratio of 3:2, a second step of mixing 5-60 wt % stainless steel powder and the powder mixture, a third step of feeding the powder mixture along with a ball having a predetermined diameter into a jar and conducting a high energy ball milling process to produce titanium nitride/titanium boride/stainless steel composite nanopowder, and a fourth step of shaping and sintering the resulting composite nanopowder.
    • 本文公开了一种制造超细晶体TiN / TiB 2复合金属陶瓷的方法。 在该方法中,通过使用钛(Ti),氮化硼(BN)和不锈钢粉末作为原料粉末的反应研磨法制备氮化钛(TiN)/硼化钛(TiB 2)/不锈钢复合纳米粉末, 得到的复合纳米粉末是液相烧结的。 该方法包括以3:2的摩尔比混合钛粉和氮化硼粉末的第一步骤,混合5-60重量%不锈钢粉末和粉末混合物的第二步骤,第三步将粉末混合物 将具有预定直径的球放入罐中并进行高能球磨工艺以制备氮化钛/硼化钛/不锈钢复合纳米粉末,以及第四步,对所得的复合纳米粉末进行成型和烧结。
    • 2. 发明申请
    • Drug fractional system using generic group code and universal drug number and method thereof
    • 药物分数系统使用通用组代码和通用药物编号及其方法
    • US20100250545A1
    • 2010-09-30
    • US12591129
    • 2009-11-10
    • Young-Whan Cho
    • Young-Whan Cho
    • G06F17/30
    • G06F19/326G06F19/00
    • A drug classification system using a generic group code and a universal drug number is developed to determine whether the drug comprises a single formulation or a composite formulation using the generic group code, understands an administration type, dose and/or formulation type of the drug, registers a universal drug number for the drug in association with the generic group code, traces back the generic group code from the universal drug number, and identifies a company name and a trade name of the drug which in turn rapidly and easily recognizes the drug; and, in addition, a drug classification method using the same. The system may manage the generic group code and the universal drug number in association with the company code, thereby enabling quick and exact management of drug information.
    • 开发了使用通用组代码和通用药物编号的药物分类系统,以确定药物是否包含单一制剂或使用通用组代码的复合制剂,了解药物的给药类型,剂量和/或制剂类型, 登记与通用组代码相关联的药物的通用药物编号,从通用药物编号中追溯通用组代码,并确定药物的公司名称和商品名称,从而快速容易地识别药物; 以及使用其的药物分类方法。 该系统可以与公司代码相关联地管理通用组代码和通用药品编号,从而快速准确地管理药物信息。
    • 5. 发明授权
    • Method of fabricating ultra-fine cermet alloys with homogeneous solid grain structure
    • 制造具有均匀固体晶粒结构的超细金属陶瓷合金的方法
    • US07217390B2
    • 2007-05-15
    • US10681009
    • 2003-10-08
    • Jae Hyeok ShimJong Ku ParkYoung Whan Cho
    • Jae Hyeok ShimJong Ku ParkYoung Whan Cho
    • B22F1/00
    • B22F1/0044C22C1/1084C22C29/06
    • The present invention relates to a method of fabricating ultra-fine grain cermet alloys with a homogenous solid solution grain structure. More particularly, the invention relates to a method of fabricating an ultra-fine TiC-base cermet alloy with a homogenous solid solution structure which does not comprise a core-rim structure in the carbide grain.The object of the present invention is to provide a method of fabricating a TiC-base cermet alloy without the core-rim structure.The above objects of the present invention could be achieved by employing a conventional sintering process (vacuum sintering) of (Ti,TM)C carbide obtained from a mechano-chemical synthesis (high energy ball-milling) from milling the powders of Ti, TM, Ni and Co metals.
    • 本发明涉及一种制造具有均匀固溶晶粒结构的超细晶粒金属陶瓷合金的方法。 更具体地说,本发明涉及一种在碳化物颗粒中不包含芯 - 边缘结构的均匀固溶体结构的超细TiC基金属陶瓷合金的制造方法。 本发明的目的是提供一种不具有芯 - 边缘结构的TiC基金属陶瓷合金的制造方法。 本发明的上述目的可以通过使用从机械化学合成(高能球磨)获得的(Ti,TM)C碳化物的常规烧结方法(真空烧结)来研磨Ti,TM粉末 ,Ni和Co金属。
    • 6. 发明申请
    • METHOD FOR MANUFACTURING TRANSITION METAL BORIDE POWDER
    • 制造金属过渡金属粉末的方法
    • US20080233032A1
    • 2008-09-25
    • US12052877
    • 2008-03-21
    • Jae-Hyeok SHIMJi-Woo KimYoung-Whan Cho
    • Jae-Hyeok SHIMJi-Woo KimYoung-Whan Cho
    • C01B35/04
    • C01B35/04
    • The present invention relates to a method for manufacturing a transition metal boride powder. The method for manufacturing a transition metal boride powder includes: i) manufacturing a mixed powder by mixing a transition metal halogenide powder and an alkali metal borohydride powder; ii) charging the mixed powder and a plurality of balls into a reaction vessel; iii) charging an inert gas into the reaction vessel and sealing the reaction vessel; iv) high energy ball milling the mixed powder and manufacturing a composite powder containing a transition metal boride and an alkali metal halogenide; v) washing the composite powder in water, dissolving the alkali metal halogenide in the water and filtering the transition metal borides; and vi) drying the filtered transition metal boride and collecting the transition metal boride powder.
    • 本发明涉及过渡金属硼化物粉末的制造方法。 过渡金属硼化物粉末的制造方法包括:i)通过混合过渡金属卤化物粉末和碱金属硼氢化物粉末制造混合粉末; ii)将混合粉末和多个球装入反应容器中; iii)将惰性气体装入反应容器并密封反应容器; iv)高能球磨混合粉末,制造含有过渡金属硼化物和碱金属卤化物的复合粉末; v)在水中洗涤复合粉末,将碱金属卤化物溶解在水中并过滤金属硼化物; 和vi)干燥过滤的过渡金属硼化物并收集过渡金属硼化物粉末。
    • 9. 发明授权
    • Method of producing ultrafine crystalline TiN/TIB2 composite cermet
    • 生产超细晶TiN / TIB2复合金属陶瓷的方法
    • US07771649B2
    • 2010-08-10
    • US11942147
    • 2007-11-19
    • Jae Hyeok ShimJi Woo KimYoung Whan Cho
    • Jae Hyeok ShimJi Woo KimYoung Whan Cho
    • B22F3/12
    • C22C29/005C22C1/053C22C33/0278
    • Disclosed herein is a method of producing an ultrafine crystalline TiN/TiB2 composite cermet. In the method, titanium nitride (TiN)/titanium boride (TiB2)/stainless steel composite nanopowder is produced through a reaction milling process using titanium (Ti), boron nitride (BN), and stainless steel powders as raw material powders, and the resulting composite nanopowder is liquid-phase sintered. The method comprises a first step of mixing titanium powder and boron nitride powder at a molar ratio of 3:2, a second step of mixing 5-60 wt % stainless steel powder and the powder mixture, a third step of feeding the powder mixture along with a ball having a predetermined diameter into a jar and conducting a high energy ball milling process to produce titanium nitride/titanium boride/stainless steel composite nanopowder, and a fourth step of shaping and sintering the resulting composite nanopowder.
    • 本文公开了一种制造超细晶体TiN / TiB 2复合金属陶瓷的方法。 在该方法中,通过使用钛(Ti),氮化硼(BN)和不锈钢粉末作为原料粉末的反应研磨法制备氮化钛(TiN)/硼化钛(TiB 2)/不锈钢复合纳米粉末, 得到的复合纳米粉末是液相烧结的。 该方法包括以3:2的摩尔比混合钛粉和氮化硼粉末的第一步骤,混合5-60重量%不锈钢粉末和粉末混合物的第二步骤,第三步将粉末混合物 将具有预定直径的球放入罐中并进行高能球磨工艺以制备氮化钛/硼化钛/不锈钢复合纳米粉末,以及第四步,对所得的复合纳米粉末进行成型和烧结。
    • 10. 发明授权
    • Drug fractional system using generic group code and universal drug number and method thereof
    • 药物分数系统使用通用组代码和通用药物编号及其方法
    • US08768722B2
    • 2014-07-01
    • US12591129
    • 2009-11-10
    • Young-Whan Cho
    • Young-Whan Cho
    • G06Q50/00
    • G06F19/326G06F19/00
    • A drug classification system using a generic group code and a universal drug number is developed to determine whether the drug comprises a single formulation or a composite formulation using the generic group code, understands an administration type, dose and/or formulation type of the drug, registers a universal drug number for the drug in association with the generic group code, traces back the generic group code from the universal drug number, and identifies a company name and a trade name of the drug which in turn rapidly and easily recognizes the drug; and, in addition, a drug classification method using the same. The system may manage the generic group code and the universal drug number in association with the company code, thereby enabling quick and exact management of drug information.
    • 开发了使用通用组代码和通用药物编号的药物分类系统,以确定药物是否包含单一制剂或使用通用组代码的复合制剂,了解药物的给药类型,剂量和/或制剂类型, 登记与通用组代码相关联的药物的通用药物编号,从通用药物编号中追溯通用组代码,并确定药物的公司名称和商品名称,从而快速容易地识别药物; 以及使用其的药物分类方法。 该系统可以与公司代码相关联地管理通用组代码和通用药品编号,从而快速准确地管理药物信息。